Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis.

Area of Science:

• Critical Care Medicine
• Immunology
• Pharmacology

Background:

• Severe sepsis and septic shock are life-threatening conditions with high mortality rates.
• The role of anti-tumour necrosis factor (TNF)-α therapy in managing these conditions remains debated.
• Understanding the efficacy of anti-TNF-α agents is crucial for optimizing patient outcomes.

Purpose of the Study:

• To conduct a meta-analysis evaluating the efficacy of anti-tumour necrosis factor (TNF)-α therapies compared to placebo.
• To determine the impact of anti-TNF-α therapy on mortality in patients with severe sepsis or septic shock.
• To explore potential benefits in specific patient subgroups, including those with shock or elevated IL-6 levels.

Main Methods:

• A systematic literature search identified relevant randomized controlled trials (RCTs).
• Meta-analysis was performed to calculate the overall risk ratio (OR) and 95% confidence intervals (95% CI).
• Subgroup and sensitivity analyses were conducted to assess treatment effects in different patient populations and study characteristics.

Main Results:

• Seventeen studies involving 8971 patients were analyzed.
• Pooled anti-TNF-α therapy showed a significant reduction in 28-day all-cause mortality (OR=0.91, 95% CI: 0.83-0.99).
• Anti-TNF-α antibodies, especially monoclonal antibodies, demonstrated improved survival, while receptor blockers did not show significant benefits. Trends suggest improved survival in patients with high IL-6 or shock.

Conclusions:

• Anti-tumour necrosis factor (TNF)-α monoclonal antibody immunotherapy significantly reduces mortality in severe sepsis patients prior to shock.
• Anti-TNF-α therapy may offer survival benefits for patients experiencing shock or with elevated interleukin-6 (IL-6) levels.
• The findings support the potential role of specific anti-TNF-α agents in managing severe sepsis and septic shock.